Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories and Gedeon Richter have announced the positive results of Phase III clinical trial of cariprazine (RGH-188).
Subscribe to our email newsletter
Cariprazine is an antipsychotic agent used to treat acute mania associated with bipolar I disorder.
This Phase III, multicenter, double-blind, placebo- controlled, parallel-group study evaluated the efficacy, safety, and tolerability of cariprazine monotherapy in patients with acute mania.
The study demonstrated that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.
Th drug candidate is also being evaluated in clinical studies for patients with schizophrenia, bipolar depression, and as an adjunct treatment in MDD.